NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade
A - Wilkes 2026/2027 -- 2026/2027 Official Exam
OBJECTIVE ASSESSMENT - EXAM
NSG552 / NSG 552 Exam 2 (Latest 2026/2027):
Psychopharmacology | Questions and
Verified Answers | 100% Correct | Grade A -
Wilkes 2026/2027 -- 2026/2027 Official Exam
75 100%
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
Neurobiology & Psychopharmacology Substance Use Disorders
Antidepressants & Mood Stabilizers Psychopharmacology in Special Populations
Antipsychotics & Anxiolytics
COVER PAGE - 1
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
, SECTION 1 | Neurobiology & Psychopharmacology | Q1-Q15
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100%
Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam 2026/2027
Q1. Question 1 of 75
1. A 32-year-old patient with major depressive disorder is started on a selective serotonin
reuptake inhibitor. The prescriber explains that the medication works by blocking the reuptake
of serotonin in the synaptic cleft. Which cellular structure is directly responsible for removing
serotonin from the synaptic cleft after neuronal signaling?
A. The serotonin transporter protein located on the presynaptic neuronal membrane
B. The postsynaptic receptor complex that undergoes conformational change upon serotonin
binding
C. The monoamine oxidase enzyme found within the mitochondrial matrix of the presynaptic
neuron
D. The vesicular monoamine transporter that packages serotonin into synaptic vesicles for storage
Correct Answer: A
Rationale:
The serotonin transporter (SERT) is a membrane protein on the presynaptic neuron that actively transports serotonin
from the synaptic cleft back into the presynaptic terminal, terminating the synaptic signal. SSRIs block this transporter,
increasing serotonin availability in the synapse. Monoamine oxidase breaks down serotonin inside the neuron (not in the
synapse), and the vesicular transporter packages serotonin into vesicles rather than removing it from the cleft. The
postsynaptic receptor is the target of serotonin, not the mechanism of its removal.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
2026/2027 | Passing Score: 80% | Page 2 of 61
, Q2. Question 2 of 75
2. A psychiatric nurse practitioner is considering prescribing a new medication for a
45-year-old patient who takes multiple medications for chronic medical conditions. The patient
takes a CYP3A4 inhibitor for a fungal infection. How will this enzyme inhibitor most
significantly affect the metabolism of a psychotropic medication that is primarily metabolized
by CYP3A4?
A. It will decrease the metabolism of the psychotropic medication, potentially leading to elevated
plasma levels and increased risk of toxicity
B. It will increase the rate of metabolism of the psychotropic medication, requiring a higher dose to
achieve therapeutic effect
C. It will have no clinically significant effect because CYP enzymes are not involved in psychotropic
medication metabolism
D. It will shift the metabolic pathway to an alternative cytochrome enzyme, eliminating the risk of
drug-drug interactions
Correct Answer: A
Rationale:
CYP3A4 is responsible for metabolizing approximately 50 percent of all medications. An inhibitor of this enzyme reduces
its metabolic activity, leading to decreased clearance of drugs that rely on this pathway. This results in elevated plasma
concentrations of the affected psychotropic medication, increasing the risk of adverse effects and toxicity. The dose
would need to be reduced, not increased. Enzyme inhibition does not eliminate drug interactions, and claiming CYP
enzymes are uninvolved contradicts well-established pharmacokinetic principles.
Q3. Question 3 of 75
3. A 28-year-old patient with generalized anxiety disorder is prescribed a benzodiazepine that
acts as a positive allosteric modulator at the GABA-A receptor. The patient asks the nurse how
the medication reduces anxiety. Which explanation best describes the mechanism of action?
A. The medication enhances the effect of GABA when it binds to its receptor, increasing chloride
ion influx and producing neuronal hyperpolarization
B. The medication directly stimulates GABA release from presynaptic vesicles, flooding the
synapse with inhibitory neurotransmitter
C. The medication blocks glutamate binding at NMDA receptors, reducing excitatory
neurotransmission throughout the cerebral cortex
D. The medication inhibits the reuptake of GABA into the presynaptic terminal, prolonging its
inhibitory action in the synaptic cleft
Correct Answer: A
Rationale:
Benzodiazepines are positive allosteric modulators that bind to a site distinct from the GABA binding site on the GABA-A
receptor complex. They enhance the affinity of GABA for its receptor and increase the frequency of chloride channel
opening. This increases chloride ion influx, hyperpolarizing the neuron and making it less likely to fire, which produces the
anxiolytic, sedative, and muscle-relaxant effects. Benzodiazepines do not directly stimulate GABA release or block
glutamate receptors.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
2026/2027 | Passing Score: 80% | Page 3 of 61
, Q4. Question 4 of 75
4. A 55-year-old patient with schizophrenia has been taking a first-generation antipsychotic for
several years. The nurse observes rhythmic, involuntary movements of the patient's tongue,
lips, and jaw that persist even during sleep. Which neurotransmitter receptor alteration best
explains this long-term adverse effect?
A. Upregulation of dopamine D2 postsynaptic receptors in the nigrostriatal pathway due to chronic
receptor blockade
B. Downregulation of serotonin 5-HT2A receptors in the prefrontal cortex leading to excessive
dopaminergic signaling
C. Hypersensitivity of muscarinic cholinergic receptors in the basal ganglia secondary to prolonged
anticholinergic effects
D. Desensitization of GABA-A receptors in the cerebellum resulting in disinhibition of motor
coordination pathways
Correct Answer: A
Rationale:
Tardive dyskinesia is caused by chronic blockade of dopamine D2 receptors in the nigrostriatal pathway, which leads to
compensatory upregulation (supersensitivity) of these receptors. When the receptors become hypersensitive, even
normal levels of dopamine produce excessive dopaminergic signaling, resulting in the characteristic involuntary
movements. This is why tardive dyskinesia can be irreversible even after discontinuing the causative medication.
Serotonin, muscarinic, and GABA receptor changes do not directly account for this specific movement disorder.
Q5. Question 5 of 75
5. A psychiatric nurse is reviewing the pharmacokinetic profile of a new psychotropic
medication for a 70-year-old patient. The medication has a half-life of 24 hours. Approximately
how many days will it take for this medication to reach steady-state plasma concentration with
consistent daily dosing?
A. Approximately 2 to 3 days, since steady state is achieved after two half-lives in most adult
patients
B. Approximately 10 days, because elderly patients require twice as long to reach steady state due
to decreased hepatic blood flow
C. Approximately 5 days, since steady state is generally reached after 4 to 5 half-lives of consistent
dosing
D. Approximately 1 day, because medications with long half-lives reach steady state more rapidly
than short-acting agents
Correct Answer: C
Rationale:
Steady state is achieved when the rate of drug administration equals the rate of elimination, which occurs after
approximately 4 to 5 half-lives. For a medication with a 24-hour half-life, steady state is reached in approximately 5 days
(5 x 24 hours = 120 hours). This principle applies regardless of patient age, although elderly patients may have altered
pharmacokinetics that affect the actual half-life. Two half-lives reaches only 75 percent of steady state, and one half-life
reaches only 50 percent.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
2026/2027 | Passing Score: 80% | Page 4 of 61
A - Wilkes 2026/2027 -- 2026/2027 Official Exam
OBJECTIVE ASSESSMENT - EXAM
NSG552 / NSG 552 Exam 2 (Latest 2026/2027):
Psychopharmacology | Questions and
Verified Answers | 100% Correct | Grade A -
Wilkes 2026/2027 -- 2026/2027 Official Exam
75 100%
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
Neurobiology & Psychopharmacology Substance Use Disorders
Antidepressants & Mood Stabilizers Psychopharmacology in Special Populations
Antipsychotics & Anxiolytics
COVER PAGE - 1
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
, SECTION 1 | Neurobiology & Psychopharmacology | Q1-Q15
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100%
Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam 2026/2027
Q1. Question 1 of 75
1. A 32-year-old patient with major depressive disorder is started on a selective serotonin
reuptake inhibitor. The prescriber explains that the medication works by blocking the reuptake
of serotonin in the synaptic cleft. Which cellular structure is directly responsible for removing
serotonin from the synaptic cleft after neuronal signaling?
A. The serotonin transporter protein located on the presynaptic neuronal membrane
B. The postsynaptic receptor complex that undergoes conformational change upon serotonin
binding
C. The monoamine oxidase enzyme found within the mitochondrial matrix of the presynaptic
neuron
D. The vesicular monoamine transporter that packages serotonin into synaptic vesicles for storage
Correct Answer: A
Rationale:
The serotonin transporter (SERT) is a membrane protein on the presynaptic neuron that actively transports serotonin
from the synaptic cleft back into the presynaptic terminal, terminating the synaptic signal. SSRIs block this transporter,
increasing serotonin availability in the synapse. Monoamine oxidase breaks down serotonin inside the neuron (not in the
synapse), and the vesicular transporter packages serotonin into vesicles rather than removing it from the cleft. The
postsynaptic receptor is the target of serotonin, not the mechanism of its removal.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
2026/2027 | Passing Score: 80% | Page 2 of 61
, Q2. Question 2 of 75
2. A psychiatric nurse practitioner is considering prescribing a new medication for a
45-year-old patient who takes multiple medications for chronic medical conditions. The patient
takes a CYP3A4 inhibitor for a fungal infection. How will this enzyme inhibitor most
significantly affect the metabolism of a psychotropic medication that is primarily metabolized
by CYP3A4?
A. It will decrease the metabolism of the psychotropic medication, potentially leading to elevated
plasma levels and increased risk of toxicity
B. It will increase the rate of metabolism of the psychotropic medication, requiring a higher dose to
achieve therapeutic effect
C. It will have no clinically significant effect because CYP enzymes are not involved in psychotropic
medication metabolism
D. It will shift the metabolic pathway to an alternative cytochrome enzyme, eliminating the risk of
drug-drug interactions
Correct Answer: A
Rationale:
CYP3A4 is responsible for metabolizing approximately 50 percent of all medications. An inhibitor of this enzyme reduces
its metabolic activity, leading to decreased clearance of drugs that rely on this pathway. This results in elevated plasma
concentrations of the affected psychotropic medication, increasing the risk of adverse effects and toxicity. The dose
would need to be reduced, not increased. Enzyme inhibition does not eliminate drug interactions, and claiming CYP
enzymes are uninvolved contradicts well-established pharmacokinetic principles.
Q3. Question 3 of 75
3. A 28-year-old patient with generalized anxiety disorder is prescribed a benzodiazepine that
acts as a positive allosteric modulator at the GABA-A receptor. The patient asks the nurse how
the medication reduces anxiety. Which explanation best describes the mechanism of action?
A. The medication enhances the effect of GABA when it binds to its receptor, increasing chloride
ion influx and producing neuronal hyperpolarization
B. The medication directly stimulates GABA release from presynaptic vesicles, flooding the
synapse with inhibitory neurotransmitter
C. The medication blocks glutamate binding at NMDA receptors, reducing excitatory
neurotransmission throughout the cerebral cortex
D. The medication inhibits the reuptake of GABA into the presynaptic terminal, prolonging its
inhibitory action in the synaptic cleft
Correct Answer: A
Rationale:
Benzodiazepines are positive allosteric modulators that bind to a site distinct from the GABA binding site on the GABA-A
receptor complex. They enhance the affinity of GABA for its receptor and increase the frequency of chloride channel
opening. This increases chloride ion influx, hyperpolarizing the neuron and making it less likely to fire, which produces the
anxiolytic, sedative, and muscle-relaxant effects. Benzodiazepines do not directly stimulate GABA release or block
glutamate receptors.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
2026/2027 | Passing Score: 80% | Page 3 of 61
, Q4. Question 4 of 75
4. A 55-year-old patient with schizophrenia has been taking a first-generation antipsychotic for
several years. The nurse observes rhythmic, involuntary movements of the patient's tongue,
lips, and jaw that persist even during sleep. Which neurotransmitter receptor alteration best
explains this long-term adverse effect?
A. Upregulation of dopamine D2 postsynaptic receptors in the nigrostriatal pathway due to chronic
receptor blockade
B. Downregulation of serotonin 5-HT2A receptors in the prefrontal cortex leading to excessive
dopaminergic signaling
C. Hypersensitivity of muscarinic cholinergic receptors in the basal ganglia secondary to prolonged
anticholinergic effects
D. Desensitization of GABA-A receptors in the cerebellum resulting in disinhibition of motor
coordination pathways
Correct Answer: A
Rationale:
Tardive dyskinesia is caused by chronic blockade of dopamine D2 receptors in the nigrostriatal pathway, which leads to
compensatory upregulation (supersensitivity) of these receptors. When the receptors become hypersensitive, even
normal levels of dopamine produce excessive dopaminergic signaling, resulting in the characteristic involuntary
movements. This is why tardive dyskinesia can be irreversible even after discontinuing the causative medication.
Serotonin, muscarinic, and GABA receptor changes do not directly account for this specific movement disorder.
Q5. Question 5 of 75
5. A psychiatric nurse is reviewing the pharmacokinetic profile of a new psychotropic
medication for a 70-year-old patient. The medication has a half-life of 24 hours. Approximately
how many days will it take for this medication to reach steady-state plasma concentration with
consistent daily dosing?
A. Approximately 2 to 3 days, since steady state is achieved after two half-lives in most adult
patients
B. Approximately 10 days, because elderly patients require twice as long to reach steady state due
to decreased hepatic blood flow
C. Approximately 5 days, since steady state is generally reached after 4 to 5 half-lives of consistent
dosing
D. Approximately 1 day, because medications with long half-lives reach steady state more rapidly
than short-acting agents
Correct Answer: C
Rationale:
Steady state is achieved when the rate of drug administration equals the rate of elimination, which occurs after
approximately 4 to 5 half-lives. For a medication with a 24-hour half-life, steady state is reached in approximately 5 days
(5 x 24 hours = 120 hours). This principle applies regardless of patient age, although elderly patients may have altered
pharmacokinetics that affect the actual half-life. Two half-lives reaches only 75 percent of steady state, and one half-life
reaches only 50 percent.
NSG552 / NSG 552 Exam 2 (Latest 2026/2027): Psychopharmacology | Questions and Verified Answers | 100% Correct | Grade A - Wilkes 2026/2027 -- 2026/2027 Official Exam
2026/2027 | Passing Score: 80% | Page 4 of 61
